Christopher D Whelan
Overview
Explore the profile of Christopher D Whelan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
5124
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tokolyi A, Persyn E, Nath A, Burnham K, Marten J, Vanderstichele T, et al.
Nat Genet
. 2025 Mar;
57(3):616-625.
PMID: 40038547
The biological mechanisms through which most nonprotein-coding genetic variants affect disease risk are unknown. To investigate gene-regulatory mechanisms, we mapped blood gene expression and splicing quantitative trait loci (QTLs) through...
2.
Loesch D, Garg M, Matelska D, Vitsios D, Jiang X, Ritchie S, et al.
Nat Commun
. 2025 Mar;
16(1):2124.
PMID: 40032831
Genomics can provide insight into the etiology of type 2 diabetes and its comorbidities, but assigning functionality to non-coding variants remains challenging. Polygenic scores, which aggregate variant effects, can uncover...
3.
Duff E, Zetterberg H, Heslegrave A, Dehghan A, Elliott P, Allen N, et al.
Nat Med
. 2025 Jan;
PMID: 39885359
Previous studies have suggested that systemic viral infections may increase risks of dementia. Whether this holds true for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infections is unknown. Determining...
4.
Doostparast Torshizi A, Truong D, Hou L, Smets B, Whelan C, Li S
Nat Commun
. 2024 Jul;
15(1):6430.
PMID: 39080267
Parkinson's disease is highly heterogeneous across disease symptoms, clinical manifestations and progression trajectories, hampering the identification of therapeutic targets. Despite knowledge gleaned from genetics analysis, dysregulated proteome mechanisms stemming from...
5.
Chen J, Ngo A, Rodriguez-Cruces R, Royer J, Caligiuri M, Gambardella A, et al.
bioRxiv
. 2024 Mar;
PMID: 38496668
Objectives: Temporal lobe epilepsy (TLE) is commonly associated with mesiotemporal pathology and widespread alterations of grey and white matter structures. Evidence supports a progressive condition although the temporal evolution of...
6.
Loomis S, Miller R, Castrillo-Viguera C, Umans K, Cheng W, OGorman J, et al.
Neurology
. 2024 Jan;
102(3):e207919.
PMID: 38165296
Background And Objectives: Amyloid-related imaging abnormalities (ARIA) were the most common adverse events reported in the phase 3 ENGAGE and EMERGE trials of aducanumab, an anti-amyloid monoclonal antibody. ε4 carrier...
7.
Sun B, Chiou J, Traylor M, Benner C, Hsu Y, Richardson T, et al.
Nature
. 2023 Oct;
622(7982):329-338.
PMID: 37794186
The Pharma Proteomics Project is a precompetitive biopharmaceutical consortium characterizing the plasma proteomic profiles of 54,219 UK Biobank participants. Here we provide a detailed summary of this initiative, including technical...
8.
Dhindsa R, Burren O, Sun B, Prins B, Matelska D, Wheeler E, et al.
Nature
. 2023 Oct;
622(7982):339-347.
PMID: 37794183
Integrating human genomics and proteomics can help elucidate disease mechanisms, identify clinical biomarkers and discover drug targets. Because previous proteogenomic studies have focused on common variation via genome-wide association studies,...
9.
Hinckley C, Zhu Z, Chu J, Gubbels C, Danker T, Cherry J, et al.
Epilepsia
. 2023 May;
64(8):2126-2136.
PMID: 37177976
Objective: Gain of function variants in the sodium-activated potassium channel KCNT1 have been associated with pediatric epilepsy disorders. Here, we systematically examine a spectrum of KCNT1 variants and establish their...
10.
Pereira J, Janelidze S, Strandberg O, Whelan C, Zetterberg H, Blennow K, et al.
Nat Aging
. 2023 Apr;
2(12):1138-1144.
PMID: 37118533
The role of microglia in tau accumulation is currently unclear but could provide an important insight into the mechanisms underlying Alzheimer's disease (AD). Here, we measured the microglial marker soluble...